Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03445533
Title A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Idera Pharmaceuticals, Inc.
Indications

melanoma

Therapies

Ipilimumab

IMO-2125 + Ipilimumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.